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a b s t r a c t
Recapitulation of the articular cartilage microenvironment for regenerative medicine applications faces
significant challenges due to the complex and dynamic biochemical and biomechanical nature of native
tissue. Towards the goal of biomaterial designs that enable the temporal presentation of bioactive
sequences, recombinant bacterial collagens such as Streptococcal collagen-like 2 (Scl2) proteins can be
employed to incorporate multiple specific bioactive and biodegradable peptide motifs into a single con-
struct. Here, we first modified the backbone of Scl2 with glycosaminoglycan-binding peptides and cross-
linked the modified Scl2 into hydrogels via matrix metalloproteinase 7 (MMP7)-cleavable or non-
cleavable scrambled peptides. The cross-linkers were further functionalized with a tethered RGDS pep-
tide creating a system whereby the release from an MMP7-cleavable hydrogel could be compared to a
system where release is not possible. The release of the RGDS peptide from the degradable hydrogels
led to significantly enhanced expression of collagen type II (3.9-fold increase), aggrecan (7.6-fold
increase), and SOX9 (5.2-fold increase) by human mesenchymal stem cells (hMSCs) undergoing chondro-
genesis, as well as greater extracellular matrix accumulation compared to non-degradable hydrogels (col-
lagen type II; 3.2-fold increase, aggrecan; 4-fold increase, SOX9; 2.8-fold increase). Hydrogels containing
a low concentration of the RGDS peptide displayed significantly decreased collagen type I and X gene
expression profiles, suggesting a major advantage over either hydrogels functionalized with a higher
RGDS peptide concentration, or non-degradable hydrogels, in promoting an articular cartilage phenotype.
These highly versatile Scl2 hydrogels can be further manipulated to improve specific elements of
the chondrogenic response by hMSCs, through the introduction of additional bioactive and/or
biodegradable motifs. As such, these hydrogels have the possibility to be used for other applications in
tissue engineering.
Statement of Significance
Recapitulating aspects of the native tissue biochemical microenvironment faces significant challenges in
regenerative medicine and tissue engineering due to the complex and dynamic nature of the tissue. The
ability to take advantage of, mimic, and modulate cell-mediated processes within novel naturally-derived
hydrogels is of great interest in the field of biomaterials to generate constructs that more closely resem-
ble the biochemical microenvironment and functions of native biological tissues such as articular carti-
lage. Towards this goal, the temporal presentation of bioactive sequences such as RGDS on the
chondrogenic differentiation of human mesenchymal stem cells is considered important as it has been
shown to influence the chondrogenic phenotype. Here, a novel and versatile platform to recreate a high
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degree of biological complexity is proposed, which could also be applicable to other tissue engineering
and regenerative medicine applications.
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1. Introduction
Articular cartilage is a highly complex connective tissue that
covers the surface of bones in synovial joints [1]. The unique spa-
tial organization of the components of cartilage extracellular
matrix is fundamental to its ability to carry out its biomechanical
functions [2,3]. Trauma to articular cartilage and/or disease of
the joint can stimulate catabolic responses that disturb tissue
homeostasis and can lead to progressive degeneration [4]. This is
aggravated by the aneural and avascular nature of articular carti-
lage, combined with the limited ability of resident cells to migrate
to sites of injury, which contribute to a restricted capacity for self-
repair and regeneration [5]. Current clinical treatments for articu-
lar cartilage ailments, such as non-steroidal anti-inflammatory
drugs [6], viscosupplementation [4], mosaicplasty [7], autologous
chondrocyte implantation [8], microfracture [9], and periosteal
transplantation [10], generally provide short-term pain relief and
recovery of joint mobility to patients, but long-term benefits often
remain elusive [3]. The repair tissue formed as a result of the sur-
gical interventions listed here often does not exhibit the same bio-
chemical composition as native tissue, leading to inferior
biomechanical properties. Repair tissue is typically rapidly degen-
erated, ultimately leading to the failure of the intervention [4], thus
requiring additional treatment and eventually total joint arthro-
plasty [11].
To overcome the limitations of current repair strategies,
increasing efforts are aimed at the development of biomaterial
scaffolds tailored to promote chondrogenesis, notably by providing
instructive microenvironments that are reminiscent of aspects of
the native pericellular matrix (PCM) [12,13]. Cell-matrix interac-
tions are dynamic; thus, biomaterials that present temporal
changes to the presentation of bioactive cues, i.e., by harnessing
the remodeling in response of resident cells, may allow improved
control over complex processes such as chondrogenic differentia-
tion [14].
Hydrogels are three-dimensional (3D) aqueous-based matrices
that have been widely explored as scaffolds to encapsulate cells.
Many attempts have been made to recapitulate aspects of the com-
plex and dynamic cell-extracellular matrix (ECM) interactions pre-
sent in articular cartilage and other tissues by incorporating
specific bioactive and/or biodegradable components into hydrogel
systems [15–17]. Biodegradable hydrogels in particular, have been
extensively studied in cartilage repair applications to create space
for newly deposited matrix [14]. Hydrogel degradation and ECM
accumulation rates that are closely linked have been suggested
to be fundamental to optimal tissue repair [13,14].
Hydrogel biodegradability is often implemented through the
incorporation of hydrolytically or enzymatically cleavable cross-
linkers [14,18]. Hydrolytic degradation of hydrogels can be par-
tially tunable and has been shown to stimulate cell proliferation
and ECM accumulation in cartilage tissue engineering [19]. How-
ever, the rate of degradation in such gels is more dependent on
the macromer composition than on cell behavior and generally
does not comply with cellular function. In contrast, enzymatically
degradable hydrogels respond to changes in protease secretion
by encapsulated cells, allowing for cell-mediated control over
hydrogel degradation kinetics. Matrix metalloproteinases (MMPs)
and other enzymes including plasmin [14] are commonly exploited
for this purpose as they are involved in native tissue remodeling
[20–25]. The use of such enzymatic-degradation systems has also
been shown to lead to improved cartilage ECM accumulation and
elaboration [14,17,18,21].
Scl2 proteins have recently been the subject of a number of
studies as a potential alternative to mammalian collagens for tis-
sue engineering applications [21,26–32]. Scl2 proteins consist of
a characteristic repeating (Gly–Xaa–Yaa)n sequence arranged in a
triple helical conformation, but lack the bioactive sites that medi-
ate cell responses in mammalian collagens [33]. In contrast to
mammalian collagens, Scl2 proteins are non-immunogenic, non-
cytotoxic, and can be recombinantly produced in high yields with
minimal batch to batch variation [32]. Additionally, the backbone
of Scl2 helices can easily be altered to incorporate bioactive and/
or biodegradable components via tethering or site-directed muta-
genesis, in order to modulate cellular behavior [21,34]. Previously,
Scl2 proteins have been used to generate poly(ethylene glycol)
(PEG)-Scl2 hybrid hydrogels functionalized with an integrin-
binding sequence (GFPGER) to interact with smooth muscle and
endothelial cells for vascular grafts [31]. Our group has recently
developed Scl2-based scaffolds functionalized with glycosamino-
glycan (GAG)-binding peptides and/or cross-linked by
enzymatically-cleavable peptides, designed to drive the chondro-
genic differentiation of hMSCs and degradation of the hydrogels
[21,34,35].
Human mesenchymal stem cells (hMSCs) have been shown to
benefit from the presence of fibronectin in the early stages of chon-
drogenic differentiation [18,22–24]. Fibronectin gene expression
levels are also up-regulated during these early stages of chondro-
genic differentiation [24,25]. The interaction of hMSCs with this
extracellular protein via integrin-adhesive ligands is thought to
affect cell-signaling and aid condensation and differentiation into
chondrocytes [26]. More specifically, the arginine–glycine–aspartic
acid (RGD) cell-adhesive sequence present on fibronectin has been
shown to play an important role in initiating hMSC chondrogenesis
[18]. However, in the later stages of chondrogenesis, fibronectin
gene expression levels are down-regulated [26,27], allowing com-
plete differentiation of hMSCs towards chondrocytes. The RGD
motif is often used to maintain hMSC viability in hydrogels that
do not offer other inherent cell-adhesive motifs [18,28,29]. How-
ever, studies have demonstrated that the persistence of the RGD
moiety can delay or even alter the chondrogenic differentiation
of hMSCs, often leading to hypertrophy, as clearly demonstrated
in a previous study [18]. Concentration and temporal presentation
of this RGDmoiety are thus important design criteria for the devel-
opment of hydrogels that promote chondrogenic differentiation.
In this work, we designed MMP7-cleavable hydrogels based on
Scl2 functionalized within the backbone with GAG-binding pep-
tides, using concepts from our previous work and presenting RGDS
moieties that can also be released by the action of MMP7. We first
modified the backbone of Scl2 to incorporate heparin (H), hyaluro-
nic acid (HA), and chondroitin sulfate (CS)-binding sequences via
site-directed mutagenesis (Fig. 1). Recent studies have shown the
selected GAG-binding peptides to bind specifically and non-
covalently to heparin, HA, and CS, respectively [36]. The inclusion
of the HA-binding and CS-binding peptides was verified in our pre-
vious work [21] and was shown to enhance hMSC chondrogenesis.
Heparin is present in articular cartilage and is known to encourage
the recruitment of, and to form stable complexes with, growth fac-
tors such as TGF-b thus further aiding chondrogenesis in long-term
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Fig. 1. Schematic diagrams of the peptide-functionalized Scl2 proteins and resulting hydrogels. (A) Schematic diagram of the Scl2 protein containing heparin-binding and
HA-binding peptide sequences. (B) Schematic diagram of the Scl2 protein containing heparin-binding and CS-binding peptide sequences. The ‘CPPC’ domains represent the
amino acid sequences inserted at the N and C termini to aid stability of each construct. (C) Generalized structure of the peptide-functionalized Scl2 proteins and hydrogels.
For clarity, the homotrimer chains are represented as different colors, and the triple helical motif has been opened out to show the three chains. The approximate locations of
the heparin-binding sites are displayed in the construct. The 4-arm acrylate-functionalized MMP7-cleavable and non-cleavable ScrMMP7 peptides were conjugated to the
Scl2 proteins via thiol-acrylate reactions to generate hydrogels. The cyclic RGDS peptide was conjugated to the 4-arm acrylate-functionalized MMP7-cleavable and non-
cleavable ScrMMP7 peptides via thiol-acrylate reactions. It should be noted that there can be multiple different permutations for the cleaved RGDS peptide products i.e., with
and without the Scl2 protein. Adapted from [35]. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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culture [16,19,21]. To provide RGDS binding sites that have the
potential to be enzymatically released from the hydrogel, we pre-
pared MMP7-cleavable peptides with 25 or 50% (molar ratio) of the
linker positions functionalized with RGDS and used these to cross-
link Scl2 based hydrogels. We demonstrated the temporal release
of RGDS from the hydrogels and investigated the effect of this
release on chondrogenesis in hMSCs.
2. Materials and methods
2.1. Materials
Rink amide resin, Fmoc-protected amino acids, N,N-
dimethylformamide (DMF), dichloromethane (DCM), 20% (v/v)
piperidine in DMF, O-benzotriazole-N,N,N0,N0-tetramethyluronium-
hexafluoro-phosphate (HBTU), and diisopropylethylamine (DIEA)
were purchased from AGTC Bioproducts (UK). MMP7 fluorogenic
substrate was purchased from Merck Millipore (UK). All primary
and secondary antibodies used for immunohistochemistry were
purchased from Abcam (UK). All other chemicals were purchased
from Sigma–Aldrich (UK). All chemicals were used as provided
by the manufacturers. Recombinant Scl2 proteins were expressed
in Escherichia coli (E. coli) BL21-DE3 and purified as described in
Section 2.3.
2.2. Peptide synthesis and purification
The MMP7-cleavable (PLELRA) and non-cleavable scrambled
MMP7 (ScrMMP7; PALLRE) peptides (Fig. S1) were synthesized
manually on a 2 mmol scale using standard Fmoc solid phase pep-
tide synthesis techniques as previously described [36]. Two Fmoc-
Lys(Mtt)-OH were also coupled to the peptides at the N- and C-
termini, selectively deprotected with 5% (v/v) trifluoroacetic acid
(TFA) in DCM, and reacted with an excess of acryloyl chloride to
enable acrylate group functionalization. A cyclic RGDS peptide
(GRGDSC) was synthesized on a 1 mmol scale on 2-chlorotrityl
chloride resin (100–200 mesh; VWR) (Fig. S1).
2.3. Streptoccocal collagen-like 2 protein synthesis and purification
The gene constructs used were based on the DNA sequence for
the fragment of the Scl2.28 allele (Q8RLX7) of Streptococcus pyoge-
nes encoding the combined globular and collagen-like portions of
the Scl2.28 protein, but lacking the C terminal attachment domain
as previously described [32,33,37]. Constructs included an addi-
tional pepsin cleavage and spacer sequence, LVPRGSP, between
the N terminal globular domain (V) and the following (Gly–Xaa–Yaa)n
collagen-like (CL) domain sequences. The construct prepared for
this study (termed HHACS-Scl2) contained a HA-binding (RYPISR
PRKR) or a CS-binding (YKTNFRRYYRF) sequence between two CL
domains (Fig. 1). In addition, each of the two CL domains included
heparin-binding (GRPGKRGKQGQK) sequences integrated within
the triple helical structure, as previously described [32,33,37]. To
stabilize the triple helix and allow for functionalization via thiol-
acrylate chemistry, the N- and C-termini of this initial construct
included an additional GGPCPPC sequence. This DNA sequence
was synthesized commercially with codon optimization for
expression in E. coli (GeneArt Gene Synthesis, Germany). The
sequences of the initial and final constructs were confirmed by
sequencing prior to transformation and protein expression.
The final DNA sequences were sub-cloned into the pColdI
(Takara Bio, Japan) vector systems for expression in E. coli
(Fig. S2) in order to add an N-terminal His6-tag [32,33,37]. For pro-
tein production, a selected positive clone was transformed and
then expanded in flask culture. The pColdI constructs were
expressed in the E. coli BL21-DE3 strain. The selected positive clone
was later confirmed using gene sequencing. Cells were grown in 2
 yeast extract–tryptone (YT) media with ampicillin (100 lg/mL)
at 37 C, with shaking at 200 rpm until the A600 absorbance read-
ing reached an optical density in the range 3–6 A.U. Cells were then
cooled to 25 C and 1 mM isopropyl b-D-thiogalactopyranoside
(IPTG) was added to induce protein expression. After 10 h incuba-
tion, cells were further cooled to 15 C for 14 h, after which the
cells were harvested by centrifugation (12,000g, 60 min) at 4 C.
For protein extraction, each 1 g of cell paste was resuspended in
20 mL of 20 mM sodium phosphate buffer at pH 8.0 and the cells
ruptured by sonication on ice using a Misonix S4000 instrument
with an Enhance Booster #1 probe [32,33,37]. Clarified lysate
was obtained by centrifugation (12,000g for 30 min, 4 C), adjusted
to pH 2.2 and held at 4 C for 16 h. Any precipitate that had formed
was removed by centrifugation (12,000g for 30 min, 4 C) and the
supernatant, containing the collagen, was treated by pepsin
(0.01 mg/mL) for 16 h at 4 C. Collagen was concentrated and buf-
fer exchanged into 20 mM sodium phosphate buffer, pH 8.0 using a
10 kDa cross-flow filtration membrane (Pall Life Sciences). Purity
was verified by 12% (w/v) sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS–PAGE) and matrix-assisted laser desorp-
tion spectroscopy (MALDI; Waters) [32,33,37].
2.4. Characterization of functionalized Scl2 proteins
Circular dichroism (CD) spectra of the HHACS-Scl2 protein in
H2O were recorded on a Jasco J-715 spectropolarimeter controlled
by the Jasco Spectra Manager software equipped with a Jasco PTC-
348WI Peltier temperature control system using a quartz cuvette
with a path length of 0.1 mm. The ellipticity at 220 nm was mon-
itored [21,31] as the sample temperature was increased from 25
to 40 C with an average temperature slope of 10 C/h to determine
the thermal transitions. The ellipticity was normalized to the path
length and number of amino acid residues and plotted against
temperature.
The HHACS-Scl2 protein was analyzed using Fourier transform
infrared (FTIR) spectroscopy on a Perkin Elmer Spectrum One spec-
trometer as previously described [21,31]. FTIR spectra were taken
with a scanning wavenumber range from 4000 to 650 cm1.
2.5. Preparation of Scl2 hydrogels
To prepare hydrogels, the HHACS-Scl2 protein was re-
suspended at 100 mg/mL in chondrogenic medium (high-glucose
(4.5 g/L) Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen,
UK) supplemented with 0.1 mM dexamethasone, 1% (v/v) peni-
cillin streptomycin, 50 lg/mL L-proline, 50 lg/mL ascorbate-2-
phosphate, 1  insulin-transferrin-selenium (ITS) Premix (BD Bio-
sciences, UK), and 10 ng/mL TGF-b3 (Lonza, UK)) at room temper-
ature. The acrylate-functionalized MMP7-cleavable and non-
cleavable ScrMMP7 peptides were dissolved separately in 4 mM
triethanolamine (TEA) in chondrogenic medium. In selected
MMP7-cleavable and non-cleavable ScrMMP7 peptide samples,
the cyclic RGDS peptide was dissolved and reacted (2 h, 37 C, pH
7.4) to modify 25% or 50% (on a molar basis) of the acrylates and
the resulting solutions were dialyzed against H2O overnight to
remove unreacted by-products. For hydrogel formation, equimolar
concentrations of the MMP7-cleavable and non-cleavable
ScrMMP7 peptides were reacted (10 min, 37 C, pH 7.4) to mod-
ify > 95% of the thiols on the HHACS-Scl2 protein. Prior to gelation,
the resulting solutions were sterile-filtered and pipetted in
50 lL aliquots to generate 6 homogeneous hydrogel types:
MMP7-HHACS-Scl2, MMP7-HHACS-lowRGDS-Scl2, MMP7-
HHACS-highRGDS-Scl2, ScrMMP7-HHACS-Scl2, ScrMMP7-HHACS-
lowRGDS-Scl2, and ScrMMP7-HHACS-highRGDS-Scl2. Following
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gelation, the wells were slowly topped up with chondrogenic
medium.
2.6. Hydrogel characterization
2.6.1. Morphological characterization
Hydrogels were imaged by multi-photon second harmonic gen-
eration (MP-SHG) in PBS using a Leica SP5 inverted microscope
equipped with a MaiTai HP DeepSee multi-photon laser (Spectra-
physics) on a 25 NA objective. Second harmonic signal was gen-
erated at 900 nm and detected on a photomultiplier tube (PMT)
(435–465 nm).
2.6.2. Mechanical characterization
Mechanical properties of the hydrogels were evaluated by oscil-
latory parallel plate rheology (Advanced Rheometer AR2000ex
with AR Instrument Software fitted with a Peltier temperature con-
trol system, TA instruments). Samples were tested at 37 C using
an 8 mm diameter parallel steel plate. All samples were individu-
ally prepared immediately prior to testing. Two sequential sweeps
were applied; (1) time sweep for 2 h at 0.1% strain and 6.28 rad/s
angular frequency and (2) strain sweep from 0.01 to 100% at
6.28 rad/s angular frequency. For all samples, a compression load
of 0.5 N was exerted during testing.
Hydrogels were also tested using dynamic mechanical analysis
(DMA) in unconfined compression mode using a Bose Electroforce
testing machine equipped with a 22.5 N load cell. For DMA, sam-
ples were incubated in PBS for 24 h prior to testing to ensure sam-
ples were in an equilibrium state and dimensions were measured
in wet state using digital calipers. Samples were pre-loaded to
0.05 N, compressed to 10% strain at a crosshead speed of 0.5%
strain/min, followed by a frequency sweep from 0.1 Hz to 10 Hz.
The compressive moduli were calculated from the linear portion
of the stress–strain curve.
2.6.3. GAG binding
Binding and retention of specific GAGs to the heparin-binding,
HA-binding, and CS-binding peptide sequences, incorporated into
the Scl2 backbone, was evaluated using fluorescein isothiocyanate
(FITC)-labeled heparin, HA, and CS (Creative PEGWorks, UK). Scl2
proteins were coated onto 96-well plates, incubated at 37 C for
24 h, washed three times in PBS, incubated in 1% (w/v) bovine
serum albumin (BSA) in PBS for 5 h and washed three times in
PBS to prepare the assay plates. These were incubated in 0.5 mg/
mL FITC-labeled heparin, HA, or CS for 24 h, washed three times
in PBS to remove unbound fluorescent GAGs, and kept in PBS at
37 C between measurements in the plate. The relative binding of
fluorescently-labeled heparin, HA, or CS was normalized to the
highest level of fluorescence intensity measured from each exper-
iment to give a single 100% signal level that was used as a basis for
normalization.
To study the release of heparin, HA, or CS from the hydrogels,
the constructs were processed as described above for Scl2 proteins
coated onto 96-well plates. After 1, 3, and 7 days, PBS was removed
and fluorescence intensities of the supernatants were measured to
evaluate GAG binding and retention. Samples were excited at
485 nm, and the fluorescence emission intensity was measured
at 525 nm. The relative binding of heparin, HA, or CS was normal-
ized to the highest level of fluorescence intensity at the first time
point.
2.7. hMSC culture
Bone marrow-derived hMSCs were purchased from PromoCell
GmbH (Germany). The multilineage differentiation capacity of
the hMSCs was verified by PromoCell GmbH prior to purchase.
hMSCs were seeded at 4000 cells per cm2 and cultured in mes-
enchymal stem cell growth medium (MSCGM) (PromoCell GmbH,
Germany). hMSCs were incubated at 37 C in a 5% CO2 atmosphere
and the mediumwas changed every three days. The cells were har-
vested at approximately 80% confluency with 0.025% (w/v) trypsin-
EDTA in PBS, centrifuged, and sub-cultured in MSCGM. Passage 6
hMSCs were used for all cell experiments.
2.8. Cell seeding and culture in hydrogels
hMSCs were homogeneously dispersed at 8  106 cells per mL
in pre-made 100 mg/mL HHACS-Scl2 solutions containing chon-
drogenic medium as defined in Section 2.5. Hydrogels were formed
in this solution as described above through the addition of cross-
linking peptide. Aliquots (50 lL) of the mixture were pipetted in
a non-tissue culture treated 48-well plate and allowed to gel for
30 min at 37 C in a 5% CO2 atmosphere before slowly adding
1 mL of chondrogenic medium. Hydrogels were incubated at
37 C in a 5% CO2 atmosphere for up to six weeks with the medium
changed every three days.
2.9. Weight change, enzymatic activity assay, and RGDS peptide
release
Hydrogel dry weights were measured over time in the absence
of cells to evaluate their degradation in vitro. Hydrogels were incu-
bated in chondrogenic medium for 24 h at 37 C in a 5% CO2 atmo-
sphere. The hydrogels were then incubated in chondrogenic
medium with exogenous enzymes (30 ng/mL) at 37 C in a 5%
CO2 atmosphere for one week with medium changes and dry
weight measurements after lyophilization taken daily. Percentage
weight change was normalized to day 0. Degradation by recombi-
nant human MMP1, MMP2, MMP7, and MMP13 (AnaSpec, USA)
was tested against a negative control (chondrogenic medium
alone) and a positive control (0.2 lg/mL trypsin). Next, cell-
seeded hydrogels were incubated in chondrogenic medium at
37 C in a 5% CO2 atmosphere for six weeks, and dry weight mea-
surements after lyophilization were taken after 0, 1, 3, 7, 14, 21, 28,
and 42 days of culture. Percentage weight change corresponding to
the cumulative effect of cell proliferation, cartilage-like matrix
deposition, and hydrogel degradation was normalized to day 0.
At each time point, 1 mL of medium was also removed, sterile-
filtered, and analyzed for MMP7 activity using a fluorogenic MMP7
substrate assay according to the manufacturers’ instructions and
compared to a negative control (chondrogenic medium) and a pos-
itive control (30 ng/mL recombinant human MMP7).
Release of the RGDS peptide from the hydrogels was evaluated
over time in the absence of cells using cystamine-FITC as a model
substrate in place of the RGDS peptide, coupled to the acrylates of
the MMP7-cleavable and non-cleavable ScrMMP7 peptides.
Cystamine-FITC was synthesized by reacting (2 h, room tempera-
ture, pH 7.4) cystamine dihydrochloride in an equimolar ratio with
FITC (2 h in DCM) and purifying using reverse phase preparative
HPLC. The hydrogels were incubated in phenyl red-free chondro-
genic medium with exogenous recombinant human MMP7
(0.2 lg/mL) at 37 C in a 5% CO2 atmosphere. After 0, 2, 4, 6, 8,
16, and 24 h, aliquots of the supernatants were removed and
replaced with fresh medium, and their fluorescence intensities
were measured to evaluate cystamine-FITC release. Samples were
excited at 485 nm, and the fluorescence emission intensities were
measured at 525 nm, respectively. Next, cell-seeded hydrogels
were incubated in chondrogenic medium at 37 C in a 5% CO2
atmosphere for seven days, and fluorescence intensity measure-
ments of the supernatants were taken after 0, 1, 3, and 7 days of
culture to evaluate the accumulative cystamine-FITC release, as
an indicator of the RGDS peptide release from the hydrogels.
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Samples were excited at 485 nm, and the fluorescence emission
intensities were measured at 525 nm, respectively.
2.10. Cell viability and metabolic activity
hMSC-seeded hydrogels were cultured for 0, 1, 3, 7, 14, 21, 28,
and 42 days. After the culture period, the hydrogels were washed
three times in PBS and analyzed for cell viability and metabolic
activity. Cell viability was qualitatively assessed with a LIVE/
DEAD Viability/Cytotoxicity Kit (Molecular Probes, USA) accord-
ing to the manufacturers’ instructions. Fluorescence confocal
microscopy (Leica SP5 inverted microscope, Leica Microsystems,
UK) was used to visualize live (calcein; green) and dead (ethidium
homodimer-1; red) cells. The metabolic activity of cells in the
hydrogels was quantified by the AlamarBlue assay (Serotec,
USA). This assay is based on the fluorescent signal output produced
by metabolically active cells. Measurements were made at 570 nm
and 600 nm. Cell-free hydrogels and empty wells were used as
controls. All data were normalized to DNA content (described in
Section 2.11.) at each time point.
2.11. DNA, sGAG, and hydroxyproline quantification
hMSC-seeded hydrogels were cultured for 0, 1, 3, 7, 14, 21, 28,
and 42 days. After the culture period, the constructs were washed
three times in PBS and digested individually in papain digest solu-
tion (2.5 units papain/mL, 5 mM cysteine HCl, 5 mM EDTA, pH 7.4,
in PBS) at 60 C for 24 h. Papain digests were stored at 20 C until
further analysis. Digests were assayed for DNA content using the
Quant-iTTM PicoGreen Kit (Invitrogen, USA) according to the man-
ufacturers’ instructions. Measurements were made at 535 nm. The
standard curve was generated with dsDNA (Invitrogen, USA). Sul-
fated GAG (sGAG) content was quantified using the Blyscan Kit
(Biocolor, UK) according to the manufacturers’ instructions. Mea-
surements were made at 656 nm. The standard curve was gener-
ated with bovine trachea chondroitin sulfate A. Total mammalian
cell-derived collagen content was estimated by measuring the
hydroxyproline content. Unlike mammalian collagens, bacterial
collagens lack hydroxyproline, which enabled us to distinguish
between the bacterial collagen in the hydrogel structure and new
collagen deposition by the hMSCs. Papain-digested samples were
hydrolyzed in 6 N HCl at 110 C for 18 h. The hydroxyproline con-
tent of the hydrolysate was determined using the chloramine T-
Ehrlich’s reagent assay and the color change quantified spec-
trophotometrically at 560 nm [38]. The standard curve was gener-
ated with L-hydroxyproline and a factor of 10 was used to convert
from hydroxyproline to total collagen content estimation.
2.12. Histology and immunohistochemistry
After 0 and 42 days of culture, hMSC-seeded hydrogels were
washed three times in PBS, fixed with 4% (v/v) paraformaldehyde
(Electron Microscopy Sciences, USA) for 30 min at 4 C, washed
three times in PBS, permeabilized with 0.4% (v/v) Triton X-100
for 30 min, and washed again. Hydrogels were flash frozen in opti-
mal cutting temperature medium (Tissue-Tek, Fisher Scientific)
and cryosectioned at a thickness of 10 lm. Sections were trans-
ferred to treated slides (Superfrost Plus, Thermo Scientific) and
allowed to adhere for 24 h at 4 C. Slides were stained for deposited
sGAG with Alcian Blue (AB; pH 2.5) and for cell nuclei and matrix
with Haematoxylin and Eosin (H&E).
Immunohistochemical staining (IHC) was performed for colla-
gen type I, collagen type II, collagen type X, SOX9, Runx2, and
PPAR-c. Samples were pre-treated with hydrogen peroxide, an avi-
din and biotin blocking kit (Vector Labs, UK), and blocked with 5%
(v/v) goat serum. Primary antibodies were incubated overnight at
1:200 in 5% (v/v) goat serum, followed by goat anti-rabbit sec-
ondary antibody labeled with HRP at 1:100 for 1 h, stained with
a 3,30-diaminobenzidine (DAB) kit (Vector Labs, UK) for 10 min,
and counter-stained with Haematoxylin. Rabbit IgG secondary
antibody only and PBS negative controls were also tested. All
stained sections were dehydrated, mounted with Histomount
(Fisher Scientific, UK), and viewed on an Olympus BX51 micro-
scope equipped with an Olympus DP70 camera.
2.13. Gene expression analysis
hMSC-seeded hydrogels were cultured for 0, 1, 3, 7, 14, 21, 28,
and 42 days. After the culture period, the constructs were washed
three times in PBS. Total RNA was isolated using a tissue ruptor
(Qiagen, USA) to homogenize samples with RLT buffer after which
QIAshredder columns (Qiagen, USA) and the RNeasy Mini Kit (Qia-
gen, USA) were used to extract the RNA according to the manufac-
turers’ instructions. QuantiTect Reverse Transcription Kit (Qiagen,
USA) and QuantiTect SYBR Green polymerase chain reaction (PCR)
Kit (Qiagen, USA) were used to perform reverse transcription and
quantitative PCR (qPCR), respectively. Thermocycling and SYBR
Green detection were performed on a Corbett Rotorgene 6000
(Qiagen, USA) with extension at 72 C and denaturing at 95 C.
Annealing temperatures were primer specific. Data were analyzed
using the DDCt method [39]. The following primers were used:
MMP7 (Forward 50-GAGTGAGCTACAGTGGGAACA-30 and Reverse
50-CTATGACGCGGGAGTTTAACAT-30), TIMP2 (Forward 50-TGGACG
TTGGAGGAAAGAAG-30 and Reverse 50-GGGCACAATGAAGTCA
CAGA-30) at an annealing temperature of 52 C, GAPDH (Quiagen,
USA) (Forward 50-TGGTATCGTGGAAGGACTCATGA-30 and Reverse
50-ATGCCAGTGAGCTTCCCGTTCAG-30), COL1A1 (Forward 50-CAT
TAGGGGTCACAATGGTC-30 and Reverse 50-TGGAGTTCCATTTTCAC
CAG-30), COL2A1 (Forward 50-CATCCCACCCTCTCACAGTT-30 and
Reverse 50-GTCTCTGCCTTGACCCAAAG-30), COL10A1 (Forward 50-
AATGCCTGTGTCTGCTTTTAC-30 and Reverse 50-ACAAGTAAAGATTC
CAGTCCT-30), and ACAN (Forward 50-CACTGTTACCGCCACTTCCC-30
and Reverse 50-GACATCGTTCCACTCGCCCT-30) at an annealing
temperature of 60 C, Runx2 (Forward 50-CCGCCTCAGTGATT
TAGGGC-30 and Reverse 50-GGGTCTGTAATCTGACTCTGTCC-30) at
an annealing temperature of 61 C, and SOX9 (Forward 50-AACGCC
GAGCTCAGCAAG-30 and Reverse 50-ACGAACGGCCGCTTCTC-30) at
an annealing temperature of 62 C.
2.14. Statistical analysis
All cell-related experiments were repeated three times with
hMSCs from different donors and with an intra-experiment sample
size of 3. Data are presented as means ± standard deviation (SD).
Statistical significance was determined by performing analysis of
variance (ANOVA) with Bonferroni correction and with a signifi-
cance accepted at p-value < 0.05.
3. Results and discussion
3.1. Characterization of Scl2 proteins and acellular hydrogels
3.1.1. Scl2 protein characterization
Changes in the secondary structure of the modified Scl2 protein
as a consequence of the backbone functionalization were evaluated
using CD (Fig. S3). A characteristic peak present at 220 nm in the
CD spectra confirmed that the modified Scl2 adopted a triple heli-
cal structure as previously reported [21,31]. In addition, no change
in the thermal stability of the functionalized Scl2 triple helix was
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observed in the CD spectra at 37 C. In accordance with our previ-
ous findings, the addition of cysteine residues at the N- and C-
termini of the Scl2 construct likely resulted in the stabilization of
the triple helical backbone through interchain disulfide formation
[34,35,40]. Subsequent cross-linking of the functionalized Scl2 pro-
tein into hydrogels via the MMP7-cleavable and non-cleavable
ScrMMP7 peptides would likely stabilize the backbone further
[32]. It is likely that the cross-linking peptides interlocked individ-
ual Scl2 chains together thereby minimizing their mobility and
denaturation.
FTIR spectroscopy confirmed addition of the MMP7-cleavable
and scrambled non-cleavable ScrMMP7 cross-linking peptides to
the Scl2 helix, through thiol-ene conjugation (Fig. S4). The FTIR
spectra exhibited IR transmittance peaks at 1630 cm1 (C@O) that
were assigned to the amide functional group present on the Scl2
protein in all samples and used for normalization. The peak at
1110 cm1 (C–S–C) assigned to the thioether functional group, pre-
sent after peptide cross-linking, was observed in all samples except
the non-cross-linked HHACS-Scl2 control.
3.1.2. Gag-binding characteristics of functionalized Scl2
Specific binding of CS, HA, and heparin to Scl2 functionalized
with only one of the CS-, HA-, and heparin-binding peptide
sequences was confirmed by incubating the samples with FITC-
labeled GAGs (Fig. 2A–C). Some non-specific binding of the GAGs
to the non-binding Scl2 proteins was observed; however, this
was not statistically significant compared to the blank, unmodified
Scl2 protein. Furthermore, comparable release profiles of the GAGs
from all hydrogels were observed (Fig. 2D–F), possibly because the
nature of the cross-linking peptides did not affect the binding or
release of CS, HA, and heparin as the engineered binding sequences
in the Scl2 backbone were the important elements here. Further,
the dynamic microenvironment in vivo would likely result in
noticeably different binding and release of the GAGs from the
hydrogels.
3.1.3. Morphological and mechanical characterization of hydrogels
No differences in morphology were observed for the different
hydrogel formulations using MP-SHG imaging (Fig. S5). As
expected, there are no major observable differences in the macro-
scopic appearance of the hydrogel constructs without hMSCs com-
pared to those with hMSCs (Fig. S6). The theoretical total degree of
cross-linking induced by the MMP7 and ScrMMP7 peptides was
kept constant for all hydrogel formulations to maintain compara-
ble mechanical behavior, as hydrogel stiffness has been shown to
affect cellular behavior such as adhesion, proliferation, and differ-
entiation [41]. Oscillatory shear rheology was employed to confirm
hydrogel formation and determine the time to gelation for all
hydrogels (Figs. 3 and S7). All hydrogels formed after similar times
and displayed comparable storage moduli. The equilibrium storage
moduli of all hydrogel formulations remained in the linear elastic
region up to 10% strain, after which point they decreased notice-
ably to failure point. Further mechanical characterization of the
hydrogels using unconfined DMA confirmed these observations
and the compression moduli were found to be 5 kPa at 1 Hz, with
no statistical differences between the different hydrogel formula-
tions. The failure strains of the hydrogels were comparable to other
hydrogel-based systems commonly used in cartilage tissue engi-
neering for treating focal cartilage defects [42,43]. As the different
hydrogels exhibited comparable morphological and mechanical
characteristics, we were able to compare the effect of the enzymat-
ically released and non-released RGDS peptide on cell behavior,
decoupled from the mechanical properties and morphologies of
the hydrogels.
3.2. Degradation kinetics of acellular hydrogels and RGDS peptide
release
Fig. 4 shows the degradation profiles of the acellular hydrogels
when incubated with recombinant human MMP7, MMP1, MMP2,
MMP13, or trypsin. As anticipated, all hydrogels cross-linked via
the MMP7-cleavable peptide degraded considerably faster when
exposed to MMP7 compared to MMP1, MMP2, and MMP13, for
which minimal degradation was observed (Fig. 4A). Previous stud-
ies have confirmed specific cleavage of the MMP7-cleavable pep-
tide (PLELRA) in the presence of MMP7 [14,21]. A small degree of
non-specific degradation of the hydrogels by MMP1, MMP2, and
MMP13 was observed likely due to the promiscuous cleavage
activity of MMPs [20]. No statistical differences in hydrogel degra-
dation kinetics were observed based on the concentration of RGDS
peptide sequence, illustrating that MMP7 activity is not influenced
by the presence of this peptide sequence (Fig. 4B). As expected,
hydrogels cross-linked via the non-cleavable ScrMMP7 peptide
displayed minimal degradation in the presence of MMP7, validat-
ing the ScrMMP7 peptide sequence as a non-cleavable control in
agreement with previous data [21].
FITC labeled cystamine was used as a model substrate in place
of the RGDS peptide, in order to evaluate peptide release from
the hydrogels over time after incubation with MMP7. All hydrogels
cross-linked via the MMP7-cleavable peptide displayed a signifi-
cantly higher release of cystamine-FITC from the hydrogels in the
presence of MMP7. This suggests the RGDS peptide will be simi-
larly released from these hydrogels as a result of MMP7 activity,
compared to the non-degradable hydrogels that exhibited basal
levels of cystamine-FITC release (Fig. 4C). As per the experimental
design of the degradable hydrogels, not all of the RGDS peptide will
have the potential to be released within the experimental time
frame of 24 h. Our studies demonstrated that after 24 h incubation
of the MMP7-HHACS-lowRGDS-Scl2 and MMP7-HHACS-
highRGDS-Scl2 hydrogels with exogenous MMP7, 55% and
70% of the RGDS peptide has the potential to be released com-
pared to incubation with trypsin, respectively. However, it is likely
that longer exposure to or higher concentrations of MMP7 would
completely degrade the MMP7-cleavable hydrogels, thus fully
releasing the RGDS peptide.
3.3. hMSC behavior in bioactive Scl2 hydrogels
3.3.1. Cell viability and metabolic activity
hMSC viability in all hydrogels was qualitatively confirmed via a
LIVE/DEAD assay at day 42 and remained high for all hydrogels
(Fig. S8). The metabolic activity of hMSCs and DNA content also
remained elevated in all hydrogels throughout the culture period
as determined by AlamarBlue and PicoGreen assays, respectively
(Fig. 5). These results were expected due to the presence of the
heparin-, HA-, and CS-binding peptides that have the ability to
retain the cell-synthesized GAGs, and provide an environment
suitable for cell viability. These matrix components have previ-
ously been shown to improve cell viability in hydrogels and are
known to play important roles in a variety of cell–cell, cell–ECM,
and protein interactions [36,37]. The RGDS motif is widely used
for aiding cell adhesion, proliferation, and maintaining cell viability
in hydrogels [18].
3.3.2. In vitro chondrogenesis
The chondrogenic differentiation of hMSCs encapsulated within
MMP7-cleavable and non-cleavable ScrMMP7 hydrogels, with or
without conjugated RGDS peptide, was evaluated to allow decou-
pling of the effect of the degradable hydrogels from the effect of
RGDS peptide release. In effect, the presence of the MMP7-
cleavable moieties in the hydrogels and the action of encapsulated
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cells via the release of MMP7 enables the release of RGDS peptide
via enzymatic action (some directly from the cleavage and the rest
via the release of Scl2 molecules with bound RGDS peptide), in
contrast to that functionalized in non-cleavable ScrMMP7 hydro-
gels. The gene expression of encapsulated hMSC chondrogenic
markers (COL2A1, ACAN, and SOX9) (Fig. 6A–C) in the
Fig. 2. GAG binding on Scl2 proteins/hydrogels. (A–C) Binding of fluorescently-labeled (A) CS, (B) HA, and (C) heparin to Scl2 proteins. Empty wells were used as negative
control denoted ‘no material’. (D–F) Release of fluorescently-labeled (D) CS, (E) HA, and (F) heparin from Scl2 hydrogels over 1 week. The fluorescence was measured in
arbitrary units and relative binding of CS, HA, or heparin was normalized to the highest level of fluorescent intensity at the first time point to provide the fraction of CS, HA, or
heparin released over time. Values represent means ± SD. ***p < 0.001 (n = 3).
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MMP7-HHACS-lowRGDS-Scl2 hydrogels were significantly up-
regulated at multiple time points throughout the culture period,
when compared to MMP7-HHACS-Scl2 (without RGDS peptides)
and non-degradable hydrogels for which no or very low RGDS pep-
tide release is expected throughout the culture period. Specifically,
hMSCs in the MMP7-HHACS-lowRGDS-Scl2 hydrogels had signifi-
cantly greater gene expression levels of all 3 chondrogenic markers
at week 4 and week 6 (later time points) compared to all non-
degradable hydrogels. This is in accordance with prior literature,
which suggests that RGDS binding is beneficial in the early stages
of chondrogenesis but can exhibit negative effects at later stages
[18]. The gene expression profiles for COL1A1, a fibrocartilaginous
tissue marker, and COL10A1, a hypertophic cartilage marker
(Fig. 6D–E), were the lowest for hMSCs encapsulated within the
MMP7-HHACS-lowRGDS-Scl2 hydrogels compared to all non-
degradable hydrogels for which they were up-regulated or
remained at high levels at weeks 2–6. Delaying or inhibiting termi-
nal chondrocyte differentiation of hMSCs toward fibrocartilaginous
and/or hypertrophic phenotypes remains a critical challenge for
cartilage tissue engineering strategies based on MSCs in vivo since
this can result in the formation of repair tissue with inferior
mechanical properties compared to native cartilage and/or miner-
alization of the newly formed tissue [44–48]. Our hydrogel con-
structs exhibited clear decreases in collagen type I and X levels
over a period of several weeks compared to other similar systems
[49–52]. These findings were further supported by the COL2A1/
COL1A1 gene expression ratio on the MMP7-HHACS-lowRGDS-
Scl2 hydrogels, which remained high compared to all other hydro-
gel formulations throughout culture (Fig. 6F). Taken together, these
results suggest that the presence of the RGDS peptide is important
for hMSC chondrogenesis during early time points, but its contin-
ued presence appears to have a negative impact on hMSC chondro-
genesis. These results build on previously reported findings on the
effect of transient exposure to RGD peptides on chondrogenesis by
providing additional characterization of the cellular responses
(notably with regards to the fibrocartilagenous and hypertrophic
responses) in a different system [18,24].
Interestingly, hMSCs in the MMP7-HHACS-lowRGDS-Scl2
hydrogels exhibited increased gene expression levels of chondro-
genic and decreased expression of hypertrophic markers compared
to those in the MMP7-HHACS-highRGDS-Scl2 hydrogels, with
some genes/time points presenting statistically significant differ-
ences. This suggests that there may be an optimal amount of RGDS
peptide required to promote hMSC chondrogenesis in the
Fig. 3. Mechanical properties of Scl2 hydrogels. (A) Time to gelation at a temperature of 37 C, angular frequency of 6.28 rad/s, and strain of 0.5%. (B) Storage modulus
determined from strain sweep up to 1% strain at a temperature of 37 C and an angular frequency of 6.28 rad/s. (C) Dynamic mechanical analysis (DMA) used to determine the
elastic modulus of compression of hydrogels compressed to 10% strain at 0.5% strain/min and 1 Hz. Values represent means ± SD (n = 3).
Fig. 4. Degradation profile of acellular Scl2 hydrogels. (A) Degradation of hydrogels cross-linked via the MMP7-cleavable peptide and exposed to 30 ng/mL recombinant
human MMP1, 2, 7, or 13 over time characterized as dry weight loss and expressed as a percentage of initial dry weight. (B) Degradation of hydrogels cross-linked via the
MMP7-cleavable or ScrMMP7 peptides and exposed to 30 ng/mL recombinant human MMP7 over time characterized as dry weight loss and expressed as a percentage of
initial dry weight. (C) Release of cystamine-FITC from hydrogels cross-linked via the MMP7-cleavable or ScrMMP7 peptides and exposed to 0.2 lg/mL recombinant human
MMP7 over time characterized as fluorescent signal output. Trypsin-driven degradation is used as a positive control. Chondrogenic medium without exogenous enzymes is
used as a negative control. Values represent means ± SD. **p < 0.01 versus ScrMMP7-HHACS-Scl2 (n = 3).
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Fig. 5. Metabolic activity and DNA content of hMSCs cultured in Scl2 hydrogels. (A) hMSC metabolic activity in hydrogels over 6 weeks in culture. (B) DNA content of hMSCs
per construct in hydrogels cultured over 6 weeks in culture. All data normalized to day 0. Values represent means ± SD (n = 3 for each donor; N = 3 different bone marrow-
derived hMSC donors).
Fig. 6. hMSC gene expression in Scl2 hydrogels. (A) COL2A1, (B) ACAN, (C) SOX9, (D) COL1A1, and (E) COL10A1 gene expression of hMSCs encapsulated in hydrogels over
6 weeks in culture, as analyzed using the DDCt method. Data presented as a fold difference relative to undifferentiated hMSCs (calibrator) prior to encapsulation and
normalized to GAPDH (housekeeping gene). (F) COL2A1/COL1A1 gene expression ratio. Values represent means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 (n = 3 for each donor;
N = 3 different bone marrow-derived hMSC donors).
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degradable hydrogels described in this study. Additionally, more
extensive chondrogenic differentiation of hMSCs appears to be
occurring in all degradable hydrogels compared to non-
degradable hydrogels, which is likely due to less interference with
matrix deposition resulting in greater neocartilaginous tissue accu-
mulation and elaboration [14].
These findings at the gene expression level were less pro-
nounced at the protein level after 6 weeks of culture. Nevertheless,
the amount of sGAG matrix normalized to DNA content (Fig. 7A)
was greater for the MMP7-HHACS-lowRGDS-Scl2 hydrogels com-
pared to the non-degradable hydrogels. A similar trend was
observed for total collagen content normalized to DNA (Fig. 7B),
where the total collagen content in the MMP7-HHACS-lowRGDS-
Scl2 hydrogels was higher than all non-degradable hydrogels.
These results provided additional validity to the importance of
the early presence of the RGDS peptide, followed by release from
the hydrogels over time, for inducing hMSC chondrogenesis. These
results also support the use of degradable hydrogel systems, with
the hydrogel matrix being broken down and simultaneously
replaced by neocartilaginous tissue, resulting in less interference
during ECM elaboration. No statistical differences in compression
moduli were observed between all hydrogel formulations
(Figs. 7C and S9). This is likely in part because the degradable
hydrogels were replaced by significantly higher amounts of
Fig. 7. ECM accumulation and compressive modulus of hMSC-seeded Scl2 hydrogels. (A) Sulfated glycosaminoglycan (sGAG) content of tissue deposited by hMSCs in
hydrogels over 6 weeks in culture. (B) Hydroxyproline content of tissue deposited by hMSCs in hydrogels over 6 weeks in culture as an estimation of total collagen content.
(C) Dynamic mechanical analysis (DMA) used to determine the elastic modulus of compression of hMSC-seeded hydrogels compressed to 10% strain at 0.5% strain/min and
1 Hz after 6 weeks in culture. Values represent means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 (n = 3 for each donor; N = 3 different bone marrow-derived hMSC donors). (D)
Representative histological and immunohistochemical examination of hMSC-seeded hydrogels after 6 weeks in culture. Hydrogels are stained with Haematoxylin and Eosin
(H&E), Alcian Blue for sGAG, and by immunohistochemistry for collagen type I, collagen type II, and collagen type X, respectively, from top to bottom. Scale bars are 50 lm.
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Fig. 8. hMSC gene expression, construct weight change, enzymatic activity, and RGDS peptide release in Scl2 hydrogels. (A) MMP7 and (B) TIMP2 gene expression of hMSCs
encapsulated in hydrogels over 6 weeks in culture, as analyzed using the DDCt method. Data presented as a fold difference relative to undifferentiated hMSCs (calibrator)
prior to encapsulation and normalized to GAPDH (housekeeping gene). (C) Scl2 hydrogel dry weight change over time in culture with hMSCs. Weight change was normalized
to dry weight at day 0. (D) Activity of MMP7 in hydrogels over 6 weeks in culture. MMP7 activity was normalized to fluorescence signal output at day 0. (E) Accumulative
release of cystamine-FITC, as an indicator of the RGDS peptide release from hMSC-seeded hydrogels cross-linked via the MMP7-cleavable or ScrMMP7 peptides over time
characterized as fluorescent signal output. Values represent means ± SD. *p < 0.05, #p < 0.05 versus MMP7-HHACS-lowRGDS-Scl2, **p < 0.01, ***p < 0.001, ###p < 0.001 versus
MMP7-HHACS-lowRGDS-Scl2 (n = 3 for each donor; N = 3 different bone marrow-derived hMSC donors).
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cell-secreted ECM compared to the non-degradable hydrogels. The
non-degradable hydrogels that exhibited minimal degradation
accumulated significantly less ECM, resulting in their compression
moduli not being significantly higher than the degradable
hydrogels.
Histological examination of the hydrogels indicated a homoge-
neous distribution of cells and newly deposited matrix for all
hydrogels at day 42 (Figs. 7D and S10). All hydrogels displayed
high amounts of sGAG accumulation, with the exception of the
ScrMMP7-HHACS-Scl2 hydrogels, where less sGAG matrix was evi-
dent. These results further support the sGAG accumulation data.
Immunohistochemical evaluation of collagen type I, collagen type
II, and collagen type X supported the gene expression results for
all hydrogels. Staining for collagen type II was noticeably higher
for the MMP7-HHACS-lowRGDS-Scl2 hydrogels compared to the
ScrMMP7-HHACS-Scl2 hydrogels, while collagens types I and X
were decreased. Evidently, there are more open spaces in the
degradable hydrogels compared to the non-degradable hydrogels,
which is likely due to a combination of hydrogel degradation and
matrix accumulation and with additional time or in vivo incuba-
tion, these voids will likely be completely occupied with ECM.
3.3.3. hMSC-mediated RGDS release
As the RGDS peptide had a significant effect on hMSC chondro-
genesis, we anticipated to observe an effect on MMP7 gene expres-
sion and activity, a protease that is up-regulated in the early stages
of chondrogenesis and down-regulated in the later stages. MMP7
gene expression levels were significantly up-regulated in the
MMP7-HHACS-lowRGDS-Scl2 hydrogels compared to all other
hydrogel formulations at week 6 (Fig. 8A). In contrast, MMP7 gene
expression levels by hMSCs encapsulated within the ScrMMP7-
HHACS-Scl2 hydrogels were the lowest compared to all other
hydrogels. The TIMP2 gene expression levels by hMSCs (Fig. 8B),
a known tissue inhibitor of MMP7 [20], did not exhibit significant
changes between hydrogels.
While non-degradable hydrogels showed increases in weight
over time, likely as a result of ECM accumulation without material
degradation, MMP7-cleavable hydrogels exhibited decreased
weight over time despite higher ECM accumulation as the hydrogel
degraded simultaneously with the accumulation of ECM (Fig. 8C).
Furthermore, MMP7 activity was up-regulated for all hydrogel con-
structs, particularly for the MMP7-HHACS-lowRGDS-Scl2 and
MMP7-HHACS-highRGDS-Scl2 hydrogels (Fig. 8D). Additionally,
hMSC-seeded hydrogels cross-linked via the MMP7-cleavable pep-
tide demonstrated a significant release of cystamine-FITC, confirm-
ing the release of the RGDS peptide during culture, likely caused by
endogenous MMP7 secreted by hMSCs undergoing chondrogenic
differentiation (Fig. 8E).
The temporal presentation of controlled concentrations of
bioactive cues to cells in complex 3D scaffold systems holds great
promise for recapitulating the intricate and dynamic microenvi-
ronment of the native tissue [53–56]. In mimicking the native peri-
cellular microenvironment, it is of great importance to modulate
the temporal activation of cell-signaling pathways to avoid impro-
per cell differentiation and function. Our findings suggest the need
to incorporate spatial complexity within such 3D tissue-
engineered systems to further recapitulate aspects of the native
tissue environment. Additionally, more than one spatiotemporally
presented bioactive signal may be required to regenerate zonal
organization of tissues such as articular cartilage that is deemed
important for its multiple functions [57–59]. As such, the modular-
ity of our hydrogel system allows for greater control over specific
cellular processes, with potential benefits for clinical translation.
Further, our novel hydrogel paltform can be easily adapted for
numerous other regenerative medicine and tissue engineering
applications through a careful selection of tethered and backbone
modified bioactive cues.
4. Conclusions
In this work, we have developed novel hydrogels based on
collagen-mimetic proteins with cell-mediated control over the
temporal presentation of bioactive cues, in this case the RGDS pep-
tide. The enzymatic release of tethered RGDS from a hydrogel that
also incorporated peptide sequences to dynamically, specifically,
and non-covalently bind heparin, HA, and CS was shown to signif-
icantly promote hMSC chondrogenesis compared to hydrogels for
which the RGDS peptide remained tethered to the backbone
throughout the culture period. Additionally, hydrogels functional-
ized with a low concentration of the RGDS peptide resulted in
decreased collagen type I and X expression. The results in this work
highlight the importance of the temporal presentation of bioactive
cues and present an approach to achieve this degree of complexity.
This work presents an additional example of the architectural flex-
ibility and modularity of our novel collagen-mimetic hydrogel
platform and its potential utility in tissue engineering and regener-
ative medicine applications.
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